StemCell Therapy

TAIPEI, June 25, 2012 /PRNewswire-Asia/ -- TaiGen Biotechnology Company, Limited ("TaiGen") and Zhejiang Medicine Company, Limited ("ZMC") today announced that they have signed an exclusive agreement to manufacture and commercialize nemonoxacin, a novel broad-spectrum antibiotic, in China (excluding Hong Kong, and Macau). Nemonoxacin is a novel broad-spectrum non-fluorinated quinolone antibiotic under development for respiratory infections. TaiGen will be responsible for completing the Phase 3 clinical trial for community acquired pneumonia ("CAP") in China. ZMC will be responsible for manufacturing, sales and marketing of nemonoxacin in China through its wholly-owned subsidiary, XinChang Pharmaceuticals. TaiGen will retain full development and commercialization rights outside the licensed territory including Taiwan, the United States, European Union, and Japan. Under the terms of the agreement, TaiGen will receive an upfront payment of US$ 8 million from ZMC and will receive additional milestones as well as royalties on product sales. The term of the agreement is 20 years.

Nemonoxacin has demonstrated efficacy and safety in CAP and diabetic foot infection in multinational and multi-center clinical trials conducted by TaiGen. In particular, nemonoxacin has excellent activity against drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and quinolone-resistant MRSA. Nemonoxacin is taken once-a-day and available in both oral and intravenous formulations. Currently, TaiGen is completing a Phase 3 CAP trial with more than 500 patients from Taiwan and mainland China and expects to file new drug applications in Taiwan and mainland China simultaneously in early 2013.

China is one of the major antibiotic markets in the world. According to IMS, the sales of antibiotics in 2011 were approximately US$ 11 billion (RMB 68 billion) and account for almost 20% of the total pharmaceuticals sales. Rate of antibiotic resistant infections in China is among the highest in the world.

Mr. Li Chun Bo, Chairman of the ZMC, commented, "We are impressed with nemonoxacin's broad spectrum activity towards drug-resistant bacteria, in particular, MRSA, and excellent safety profile. We are excited to establish this partnership with TaiGen because of its reputation as a premier research-based biotech company in Asia. This partnership will break new ground for cross-strait collaboration in the pharmaceutical industry. Nemonoxacin will be a major addition to ZMC's antibiotic product line and significant profit driver".

Dr. Ming-Chu Hsu, President and Chief Executive Officer of TaiGen, said, "China is the world's fastest growing pharmaceutical market. It is poised to overtake Japan as the second largest pharmaceutical market. We are extremely please to establish our nemonoxacin partnership with ZMC, a first-class pharmaceutical company and major player in the Chinese antibiotics market. With nemonoxacin, TaiGen and ZMC together will bring new medicine to treat unmet medical needs in China. This partnership will not only set a new record for pharmaceutical licensing involving a Taiwanese and a mainland Chinese company but hopefully will also become a model of the future collaborations," Dr. Hsu also added, "With the conclusion of the partnership in China, we will actively pursue nemonoxacin licensing discussions in other territories such as European Union."

About Zhejiang Medicine

Zhejiang Medicine Company, Limited is a leading pharmaceutical company in China specializing in sales and distribution of pharmaceuticals and manufacturing of active pharmaceutical ingredients (vitamins and antibiotics). Its sales revenue in 2011 is US $740 million (RMB 4.8 billion). ZMC is a leader in the Chinese antibiotic market with levofloxacin, vancomycin, and teicoplanin in the product line. ZMC's Lai Li Xin, a branded levofloxacin, is one of the top selling antibiotics in China with 2011 sales exceeding US $110 million (RMB 735 million). In addition to pharmaceuticals sales, ZMC is also known for its manufacturing quality. Its vancomycin active pharmaceutical ingredient has obtained GMP qualification from US Food and Drug Administration (FDA) and exported to western countries. ZMC is publicly listed in the Shanghai Stock Exchange (600216) and has a market capitalization of RMB 11 billion.

About TaiGen Biotechnology

TaiGen Biotechnology is a leading research-based and product-driven biotechnology company in Taiwan with a wholly-owned subsidiary in Beijing, mainland China. TaiGen has full discovery research capacity in Taiwan and clinical development in mainland China/Taiwan/US. In addition to nemonoxacin, TaiGen has two other in-house discovered new chemical entities in clinical development under IND with US FDA: TG-0054, a chemokine receptor antagonist for stem cell transplantation and chemosensitization, in Phase 2 and TG-2349, a HCV protease inhibitor for treatment of chronic hepatitis infection, in Phase 1. Both TG-0054 and TG-2349 are currently in clinical development in the US.

Disclaimer

See the original post:
TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine

SHENZHEN, China, May 29, 2012 /PRNewswire-Asia/ --Beike Biotechnology Co., Ltd ("Beike") announced that it has been awarded AABB accreditation for cord blood and cord tissue banking. This accreditation has been granted following an intensive on-site assessment by AABB assessors and establishes that the level of medical, technical and administrative performance within the facility is in accordance with the AABB standards or exceeds those set by AABB. With this achievement, Beike becomes China's first and only AABB-accredited stem cell bank for both cord blood and cord tissue banking.

Ying Song, MD, PhD, Medical Director of Beike, stated, "It is a proud moment for us that Beike is the first and the only stem cell bank in China to possess AABB accreditation for both cord blood and cord tissue and this reflects our commitment to quality. It is also noteworthy to mention that Beike is among the first stem cell banks in the world to receive AABB accreditation for cord tissue banking which positions Beike as a leader in stem cell preservation."

Beike began the comprehensive AABB accreditation process in March 2010 and completed the on-site assessment in September 2011. The accreditation assessment included stem cell processing, records, document control, inspection and testing, technician training, sample identification, traceability and validations. During this audit, it was determined that Beike's medical, technical and administrative performance met the standards set by the AABB. Beike was issued its AABB certificate in January 2012.

Dr. Shengqin Ye, President of Beike, commented, "We are extremely pleased to have been granted this accreditation. With this, Beike has once again demonstrated a commitment to advanced learning, continuous improvement and innovation to sustain the highest possible level of quality and safety."

To meet AABB standards, Beike adopted new technology for stem cell processing (AXP AutoXpress system), storage (BioArchive Systems), and testing (Beckman hematology analyzer LH750 and Tecan Freedom EVOlyzer). Additionally, the company optimized its information technology platform and software systems, adding an advanced bar code management system, real-time monitoring capabilities, and an advanced enterprise resource planning (ERP) system to its call center.

About Beike Biotechnology Company:

Shenzhen Beike Biotechnology Co., Ltd. is China's leading biotechnology company focusing on banking adult stem cells and developing new cell based medicinal products. Headquartered in Shenzhen (near Hong Kong) with a flagship regenerative medicine facility at the China Medical City in Jiangsu province, Beike produces a full line of stem cell products derived from umbilical cord, cord blood and autologous bone marrow.

About AABB:

AABB (formerly the American Association of Blood Banks) is an international non-profit body dedicated to developing the highest standards in blood and cord blood banking, transfusion medicine and cellular therapy. The association is committed to improving health by developing and delivering standards, accreditation and educational programs that focus on optimizing patient and donor care and safety.

Based in the United States, AABB represents more than 2,000 institutions and 8,000 individuals in 80 countries, involved in collecting, processing, testing, distributing, or transfusing blood, blood components, or cellular therapy products.

Read more from the original source:
Beike Earns AABB Accreditation for Cord Blood and Cord Tissue Banking

16 May 2012

Angel Biotechnology Holdings plc

("Angel" or "the Company")

Angel signs new contract with ReNeuron to provide GMP (KOSDAQ: 018290.KQ - news) cell manufacturing services for completion of stroke clinical trial

Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, has signed a new contract with ReNeuron Group (Berlin: RQE.BE - news) plc (AIM:RENE) to perform GMP manufacturing services in support of the final part of the PISCES Phase 1 clinical trial of its ReN001 stem cell therapy for stroke; the value of the contract was not disclosed.

Dr Stewart White, Acting CEO, Angel Biotechnology (Berlin: A3G.BE - news) said: "Angel is very proud to be providing ReNeuron with additional manufacturing support to complete this ground breaking Phase 1 clinical trial. This contract is further recognition of the strong partnership between Angel and ReNeuron, and also reaffirms both companies commitment to provide solutions for a real clinical need."

For further information:

Angel Biotechnology Holdings plc

Lorna Peers, Finance Director +44 (0) 131 445 6077

Stewart White, Acting CEO/Commercial Director http://www.angelbio.com

See original here:
Angel Biotechnology - Angel signs new contract with ReNeuron

NEW YORK, NY--(Marketwire -03/28/12)- Biotechnology stocks have been on an impressive run this year as favorable legislation out of Washington is allowing biotech companies of all sizes to more easily navigate regulations. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Advanced Cell Technology Inc. (OTC.BB: ACTC.OB - News) and PharmAthene Inc. (AMEX: PIP - News). Access to the full company reports can be found at:

http://www.fivestarequities.com/ACTC http://www.fivestarequities.com/PIP

The Biotechnology Industry Organization (BIO) recently applauded the House Energy and Commerce Committee's passage of the Medicare Decisions Accountability Act, H.R. 452, which would repeal the Independent Payment Advisory Board (IPAB) established in the health care reform law. BIO also issued a press release applauding the Senate on the passage of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act. The JOBS Act creates an "on-ramp" to the public market for emerging growth companies, allowing them five years to focus on conducting critical research that can lead to cures for debilitating diseases before having to divert funds to costly regulations, BIO reports.

Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com and get exclusive access to our numerous stock reports and industry newsletters.

Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. Earlier this month the company filed with the Securities and Exchange Commission a proxy statement containing a shareholder proposal for a reverse split of its common stock. "This reverse stock split, which should better align the company's capital structure with its stage of development, and an accompanying Nasdaq listing application, will represent a significant step toward creating long-term shareholder value and building ACT into a world-class player in the regenerative medicine space," said Gary Rabin, chairman and CEO of ACT.

PharmAthene, Inc., a biodefense company, engages in the development and commercialization of medical countermeasures against biological and chemical weapons in the United States. For the year ended December 31, 2011, PharmAthene recognized revenue of $24.3 million, compared to $21.0 million in 2010.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.fivestarequities.com/disclaimer

Read this article:
Advanced Cell Technology and PharmAthene Poised to Benefit From Positive Legislation

Biotechnology is undoubtedly the technology of the future for it not only presents exceptional opportunities, but also gives hope for a better future with better diagnosis and treatment of diseases. In terms of potential and growth, it is not much different from the mystical dragon, and since 2012 is the year of the dragon, it is expected that it would bring in loads of good news and prosperity for this new branch of science.
The good news
For biotechnology, the last year has been strong and monumental with Tax Incentive Legislation being passed in Australia and a very strong and consistent growth in the sector which was recently followed by good news, the Senate Inquiry of the gene patents bill. Since the last year, the Australian Biotechnology has been included amongst the fifth most innovative biotech nations in the world (according to the Scientific American World View). This trend is continuing in the current year, as Australia has shown great potential in developing biotech related agricultural, medical and even environmental research.
The companies of Australian Biotech are confident that the New Year would definitely be the best and until now with tremendous growth in the sector it has proved this. Even the new startup biotech companies in Australia now stand a better chance with the Tax Incentive’s 45% refundable component, even the large corporations would now be able to reduce their R&D expenses by as much as 10%. Such a healthy growth favoring environment has allowed the Australian Biotech companies to make a mark globally and have a steadily rising status even in the competitive markets of US and Europe.
Conclusion
The Australian Biotech industry now needs to revamp itself and embrace a more authentic and transparent management. There should be better communication between the management and the stakeholders. The opportunities are in plenty and the industry environment very supportive, hence the companies should make the most of it and truly let the biotech dragon rise in this year of the dragon.

Source:
http://www.biotechblog.org/rss.xml

15-03-2012 15:54 This screencast focuses on stem cells, their sources, and their potential applications in biomedical research.

Excerpt from:
Biotechnology Screencast Session 5.m4v - Video

NOKOMIS, Fla.--(BUSINESS WIRE)--

With the global demand for biotechnology solutions to mounting health concerns growing every day, Rainbow Coral Corp. (OTCBB: RBCC.OB - News) has been working hard to deliver the kinds of breakthroughs that doctors, scientists, and researchers the world over are begging for.

Today, Rainbow BioSciences, the biotech division of Rainbow Coral Corp. (OTCBB: RBCC.OB - News) announced that it has signed a deal to acquire an interest in the cutting-edge biotech firm Nano3D Biosciences, Inc. (n3D). One of the hottest emerging biotech developers in the world, n3D is producing new tools that could challenge long-held assumptions about healthcareand change lives in the process.

The agreement is the culmination of months of work and negotiations. N3D is a terrific fit with RBCCs aggressive focus on company growth. The companys new breakthrough cell-culturing technology, the Bio-Assembler, is fully commercialized already. RBCCs participation will provide n3D with the funds for marketing and distributing the Bio-Assembler to new markets as cellular research in the biotech sector explodes around the globe.

The acquisition has RBCC well-positioned to participate in the potentially dramatic upside that many bioscience companies realize at this stage. N3Ds Bio-Assembler could be poised to revolutionize the way stem cell research and the study of other living tissues is conducted worldwide, with the potential to ultimately reduce the development timeline for new life-saving drug therapies.

For more information on Rainbow BioSciences, RBCCs biotechnology division, please visit http://www.rainbowbiosciences.com/investors.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Cell Therapeutics, Inc. (NASDAQ: CTIC - News), Biogen Idec Inc. (NASDAQ: BIIB - News), Abbott Laboratories (NYSE: ABT - News) and Elan Corp. (NYSE: ELN - News).

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC.OB - News). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit http://www.RainbowBioSciences.com/investors.

Notice Regarding Forward-Looking Statements

Excerpt from:
RBCC Closes Deal with Game Changing Biotech Firm

27 February 2012

Angel Biotechnology Holdings plc

("Angel" or "the Company")

Grant of Share Options - Enterprise Management Incentive (EMI) Scheme

Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, is pleased to announce share options totaling 16,806,723 were awarded to Dr. Stewart White, Commercial Director, under the Company's Enterprise Management Incentive (EMI) share option scheme on 24 February 2012. All share options are exercisable at a price of 0.238p per share, subject to performance and retention criteria being met and are the first share options awarded to Dr. White since his appointment last year.

The exercise dates are as follows:

Exercise Dates

Number of options

04/06/2012 - 03/06/2022

3,361,345

31/12/2012 - 30/12/2022

6,722,689

31/03/2013 - 30/03/2023

6,722,689

Dr Paul Harper, Executive Chairman of Angel Biotechnology Holdings plc said:

"The Board of Directors is delighted to award these options to Dr. White to reflect the commitment made to ensure the success of the Company."

For further information:

Angel Biotechnology Holdings plc

Lorna Peers, Finance Director +44 (0) 131 445 6077

Stewart White, Commercial Director http://www.angelbio.com

Grant Thornton, Corporate Finance

Colin Aaronson / Melanie Frean / Elliot Berg +44 (0) 20 7383 5100

Hybridan LLP (Broker)

Claire Noyce / Deepak Reddy +44 (0) 20 7947 4350

Media (Frankfurt: 725292 - news) enquiries:

The Communications Portfolio Ltd

Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029

ariane.comstive@communications-portfolio.co.uk

Notes to Editors:

Angel Biotechnology Holdings plc is a full service contract bio-manufacturing partner to biotechnology and pharmaceutical companies worldwide. Angel specialises in advanced biologics including biopharmaceutical proteins and cell therapies, such as cellular vaccines and stem cells. At present, Angel's products are principally used in pre-clinical studies and clinical trials with a view to becoming the contract manufacturer of choice on a continuing basis.

Drug development companies outsource their biopharmaceutical manufacturing requirements to Angel to reduce their own capital requirements and enable them to develop products more rapidly. In addition, Angel provides complete regulatory services and documentation to its customers while its manufacturing processes adhere to the most stringent regulatory requirements. Products are produced to current Good Manufacturing Practice (cGMP) standards as required by the US Food and Drug Administration (FDA), and in facilities that are certified to European standards by the Medicines (Xetra: 938858 - news) and Healthcare products Regulatory Agency (MHRA).

Its (Euronext: ALITS.NX - news) customers range from early-stage biotechnology companies including ReNeuron plc and US-based Pathfinder Cell Therapy, to established pharmaceutical companies such as Russian-based Materia Medica Holdings.

Angel has two facilities: Pentlands Science Park near Edinburgh where it employs 38 people, and a site in Cramlington, near Newcastle (Frankfurt: 725198 - news) -upon-Tyne, which is expected to be commissioned by the end of Q1 2012, initially employing up to 10 people.

More information is available at http://www.angelbio.com .

- Ends -

Continued here:
Angel Biotechnology - Grant of Share Options

SAN CARLOS, Calif.--(BUSINESS WIRE)--

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced that Lowell E. Sears joined its Board of Directors effective today.

Mr. Sears is currently Chairman and CEO of Sears Capital Management, a venture investment and portfolio management firm specializing in life sciences. He has been an active life science venture investor since 1994, helping to found and fund over forty companies. From 1986 until 1994, Mr. Sears was a part of the senior management team of Amgen, Inc., where he held positions of Chief Financial Officer as well as Senior Vice President responsible for the Asia Pacific Region.

"Lowell has had a distinguished biotechnology career and is highly regarded in the industry. I am delighted to welcome him to our board," said Ram Mandalam, President and CEO of Cellerant. "His broad experience in strategic planning, corporate financing and overall management and operational skills will be very useful to us as we continue to develop our programs and build shareholder value."

“On behalf of all of our directors I am delighted to welcome Lowell to our board," said Richard Rathmann, Cellerant’s Chairman of the Board. "Throughout his career at Amgen and other biotechnology companies, Lowell has been directly involved in building and developing successful companies as they advance to the next stage."

Prior to joining to Amgen, Mr. Sears held senior planning and financial positions with Atlantic Richfield Company (ARCO) from 1976 until 1986, including a period as Chief Financial Officer for its Ventures Division. Mr. Sears has served on twenty boards of directors, including roles as board chairman and audit committee chair. He currently serves on the board of SymBio Pharmaceuticals, KK, Ltd. (JASDAQ: 4582).

About Cellerant Therapeutics

Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant’s lead product, CLT-008, is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a cancer stem cell (CSC) antibody discovery program focused on therapies for acute myelogenous leukemia, multiple myeloma and myelodysplastic syndrome.

For more information, visit: http://www.cellerant.com.

See more here:
Cellerant Therapeutics Appoints Lowell E. Sears to Board of Directors

6 February 2012

Angel Biotechnology Holdings plc.

("Angel" or "the Company")

Angel signs three new GMP (KOSDAQ: 018290.KQ - news) manufacturing contracts

for Materia Medica Holding

Angel Biotechnology Holdings plc., (AIM:ABH), the biopharmaceutical contract manufacturer, is pleased to announce that it has reached agreement on three further manufacturing contracts with OOO " NPF "Materia Medica Holding" (MMH) with a combined value in excess of £4.5 million. It is expected these projects will run concurrently and take approximately 22 months to complete.

Under the proposed agreements, Angel will initiate activities within existing facilities, with a view to transferring production to its Cramlington site during 2012, which the Company is currently re-commissioning. The commission of these new agreements will come under the terms of our current umbrella pricing agreement, pending formation of the joint venture company ("JVC") announced on 17 October 2011 after which the contracts will transfer into the control of the JVC.

Dr Paul Harper, Executive Chairman, Angel Biotechnology Holdings, said:

"The commission of these three new agreements provides a robust basis for the proposed JVC between Angel and MMH and demonstrates the confidence the customer has in Angel's capabilities. These agreements will put the proposed JVC on a sure footing from the outset, but is also an excellent example of the value Angel can provide via significant alliances such as this.. I would like to thank MMH for making this commercial commitment."

Professor Oleg Epstein, General Director, OOO "NPF "Materia Medica Holding", said:

"By signing these three new agreements with Angel, MMH can act in a timely manner to bring these products to market. As core business, it is important to us that development work begins whilst the JVC is being established. I am positive this will provide the best possible start to the new JVC.

For further information:

Angel Biotechnology Holdings plc

Lorna Peers, Finance Director +44 (0) 131 445 6077

Stewart White, Commercial Director http://www.angelbio.com

Grant Thornton, Corporate Finance

Colin Aaronson / Melanie Frean / Elliot Berg +44 (0) 20 7383 5100

Hybridan LLP (Broker)

Claire Noyce/Tim Goodman/

Deepak Reddy +44 (0) 20 7947 4350

Media (Frankfurt: 725292 - news) enquiries:

The Communications Portfolio Ltd

Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029

ariane.comstive@communications-portfolio.co.uk

Notes to Editors:

Angel Biotechnology Holdings plc. is a full service contract bio-manufacturing partner to biotechnology and pharmaceutical companies worldwide. Angel specialises in advanced biologics including biopharmaceutical proteins and cell therapies, such as cellular vaccines and stem cells. At present, Angel's products are principally used in pre-clinical studies and clinical trials with a view to becoming the contract manufacturer of choice on a continuing basis.

Drug development companies outsource their biopharmaceutical manufacturing requirements to Angel to reduce their own capital requirements and enable them to develop products more rapidly. In addition, Angel provides complete regulatory services and documentation to its customers while its manufacturing processes adhere to the most stringent regulatory requirements. Products are produced to current Good Manufacturing Practice (cGMP) standards as required by the US Food and Drug Administration (FDA), and in facilities that are certified to European standards by the Medicines (Xetra: 938858 - news) and Healthcare products Regulatory Agency (MHRA).

Its (Euronext: ALITS.NX - news) customers range from early-stage biotechnology companies including ReNeuron plc. and US-based Pathfinder Cell Therapy, to established pharmaceutical companies such as Russian-based Materia Medica Holdings.

Angel has two facilities: Pentlands Science Park near Edinburgh where it employs 38 people, and a site in Cramlington, near Newcastle (Frankfurt: 725198 - news) -upon-Tyne, which is expected to be commissioned by the end of Q1 2012, initially employing up to 10 people.

More information is available at http://www.angelbio.com .

- Ends -

Read more here:
Angel Biotechnology - Contracts with Materia Medica

South Korea is playing a risky game as it has given the permission for using human eggs in cloning research despite a high level scandal in their country which involved one of their top scientists admitting to his involvement in doctored research work. Hwang Woo-suk was the scientist who had claimed that he had cloned human embryos and extracted stem cells from them but it was found out that all his claims were false. What raised eyes were when eggs required for research were donated by a female scientist in his team and this questioned the ethics of such practice. This shameful incident caused Hwang Woo-suk to resign from his post at the Seoul National University and is now facing trial for misappropriation of government funds. In order to get over the shameful act the government has again given a go ahead to use of human eggs in cloning but this time with an act of caution and under a new set of guidelines has asked that researchers should only use eggs which are to be destroyed after fertility treatments or from other legal ways and a prior license would have to be obtained from the government for undertaking research. It seems this time South Korea wants to take no chances. Via theage

Source:
http://www.biotechblog.org/rss.xml

Who said India lags behind in the arena of stem cell research? The country is growing at the rate of fifteen percent per year in the stem cell market arena and will reach the figures of $ 540 million by 2010. India has around fifteen centers which are undertaking research in the arena of stem cell. Of them five centers are involved in undertaking extensive trials in the arena of cardiology. India has all the strength to emerge as a global hub for undertaking stem cell research. Since U.S has banned stem cell research India can surely prosper in this field as it has both knowledge and technology for undertaking research in this area. With medical field making rapid moves researchers are opting for advanced techniques which can help in targeting the root cause of the diseases rather than just treatment of the symptoms and in this respect stem cell research is gaining a stronger position. One questions which is troubling my mind is if India emerges as a hub for stem cell research how will it handle the sensitive topics such as cloning and breeding of human cells. Via prminds

Source:
http://www.biotechblog.org/rss.xml

Scientists have found ways to prepare stem cells from skin of an adult rat, without harming embryos. The discovery, which was done successfully on rats, will remove the ethical concerns of using stem cells for various medical purposes. Researchers have shown that it is possible to create stem cells similar to those present in embryos from skin. So far, mature cells were considered incapable of producing stem cells. The success of the research on rat has made scientists hopeful of being able to do this in case of humans as well. If this happens, the stem cells obtained from skin cells of a person will be able to produce cells and tissues that would be genetically an exact copy of the original, dispelling any rejection by the body that was probable for a stem cell obtained from an embryo. Stem cells are totipotent–capable of developing in any kind of tissue present in the body. Such a capability is of immense benefit as they can be used to replace the damaged cells and tissues, thus providing possible cure for several diseases like diabetes, Parkinson’s and Alzheimer’s. The use of stem cells from embryo had ethical and moral concerns as the collection of stem cells damages the embryos. This many said is tantamount to murder or cannibalism. The new discovery, if successful for humans, will pave new ways for curing several diseases including those which were till now could not be treated. This will surely help cure many diseases and body defects. An advancement in this technique may also provide body organs for transplantation. The possibilities are immense but some concerns will continue to remain. The stem cells could be used rampantly for cosmetic purposes like skin grafts. This may also open a new arena of spare parts for human bodies as is available for machines. This will obviously dent the magical power of life. The cliche remains valid even here – every coin has two sides. It’s all up to us to choose the positive side. Learn more about stem cells. Source: BBC, Daily Mail Image Source: Canada.com

Source:
http://www.biotechblog.org/rss.xml

Using small many years, medical has produced alone being a small business with big guarantee for your Modern. As you move the medical industry’s full capital scarcely is higher than that relating to pharmaceutical drug organization Merck, it has an very fast rate of growth, joined with an excellent chance to innovate. Needlessly to say, next, the thought of setting up a sturdy cluster of medical businesses shows an attractive option for regional enterprise agencies. In fact, biotechnology businesses are usually capital-intensive. That they take up relatively pricey services, hire higher-end technological employees, as well as produce considerable community profits.

The particular Biotechnology Progress Group (BDG) targets the development of easy and revolutionary technology for that creation of biosimilars. The goal should be to raise the know-how along with functions with the prescription companies with ICGEB Fellow member Suggests through transferring technologies for your production and also qc connected with pharmaceutical recombinants: erythropoietin (EPO), interferon alpha 2a as well as m (IFN leader Only two), interferon toy with 1b, granulocyte nest rousing factor (G-CSF) and also Blood insulin. Your lab’s methods can be modified towards the circumstances pre-existing within Member Suggests having just minimal economic expenditure important to set-up the production facilities. That can help the fabrication set-up, we’ve got added our technology to pilot degree.

Within the last number of years, the audience has trained more than 60 to 70 scientists through Teen pharmaceutic companies operating in various ICGEB Member Says. Most of these corporations have become producing biosynthesis utilizing your systems. They are generally, not merely, deeply in love with a nearby marketplaces, however properly remain competitive for the intercontinental marketplace.

Source:
http://www.biotechblog.org/rss.xml

The creation of genetically modified ingredients along with other gardening biotechnology solutions has produced substantial public argument. The potential of creating food boosted regarding health improvements as well as growing harvest yields seemed to be tantalizing, but there seemed to be likewise popular concern about the technology’s health and the environmental dangers. The Pew Effort with Meals along with Biotechnology showcased insurance policy issues due to these kinds of discussion posts along with functioned as a trustworthy, straightforward brokerage, combining people who have differing sides to check the particular prospects in addition to problems involving garden medical.

By way of it’s reviews, reality blankets, forms along with conventions, this undertaking dished up being a highly regarded information supply upon farming biotechnology in addition to relevant coverage problems pertaining to legislators, educators, the public along with the mass media in the usa along with around the world. Although project determined it’s operate in 3 years ago, the source of information supplies remain available in this article.

In a very challenge to distinguish, road and also transfer desired alleles with QTLs for provide in addition to provide parts and also security also to make QTL bear isogenic outlines associated with grain, along with agronomic examination associated with BC2F4 Nearest Isogenic Introgressions Lines (NIILs) as many as 2 hundred BC2F5 progenies were being evaluated for your subsequent sequential 12 months for the duration of summer season ’06 inside multi-location tests.

Along with increasing environmental considerations, the one reliance on substance advices primarily based farming is being changed by bundled technique regarding conjunctive by using both organic and natural and inorganic solutions. In this context, biofertilizers are already received well being an affordable, cost-effective, renewable and also risk-free normal supply of vegetable nutritional requirements for you to sustain crop production. Moreover, along with new concentrate on organic/bio-dynamic gardening, your need for biofertilizers probably will increase with a considerably quicker rate compared to ahead of. Only at that point, we should recognize that microbe inoculants are generally ‘ecological inputs’, whoever side effects usually are ‘subtle but not dramatic’ like chemical substance inputs.

That’s why, inoculation along with good quality inoculants is a must and will always be handled as a possible insurance policies versus malfunction associated with nodulation. Your shelf life at a store and transportation has to be improved along with owing thing to consider to several ‘abiotic’ challenges. The particular quality-oriented creation and also marketing system will certainly make biofertilizers the workable organization intended for greatest customer care. Retaining most of these in view, programmes on progression of fruit juice biofertilizers and also biofertilizers-based Incorporated Source of nourishment supervision offers with regard to village plants and also medicinal flowers have already been developed. Furthermore biofertilizers pressures developed via transgenosis will likely be examined inside covered circumstances.

Really does conventional plant mating have consequences about health and the environment

In standard grow breeding, very little focus has been paid for to your achievable has an effect on of the latest place versions with meals safety or perhaps the natural environment. Conventional grow multiplying and synthetic selection can produce genecombinations that might hardly ever survive in nature. In a few scenarios, this kind of gene blends get induced uncomfortable side effects about people wellness. For instance, a developed variety of spud is discovered to consist of excessive amounts of natural toxins.

The possible influences connected with conventionally carefully bred herbs within the atmosphere or in farmers’ standard versions possess commonly not really been recently confronted with regulatory settings. Many of the worries regarding gene shift between tamed and outrageous vegetation who have arisen because of the arrival associated with genetically customized vegetation likewise pertain to traditional plants.Almost all of the earth’s food crops usually are not indigenous to his or her significant production specific zones; somewhat, they will arose in a number of distinct “centers involving origin” and have been utilized in completely new manufacturing locations by way of migration along with trade. Very tamed plants are developed worldwide as well as migration outside the house developed areas merely has hardly ever brought about a significant issue. Even though produced within their middle connected with origin, like with taters within South America or even maize within South america, hybrid cars among discriminating as well as outdoors variety have not been permanently recognized. There are several reviews regarding gene flow amongst cultivated plant life along with their outdoors relations playing with common this has not really also been

Source:
http://www.biotechblog.org/rss.xml

Modern-day biotechnology is restorative healing the entire world by means of taking nature’s individual resource as well as neurological operations. Throughout curing the world, biotechnology is decreasing the rates connected with contagious disease, overcoming life-threatening problems, generating customized treatments possible, in addition to preserving the particular lifestyles of these suffering with exceptional illnesses.
Particularly, medical provides the probable involving handling unmet healthcare desires for individuals along with cancers and HIV/AIDS while at the same time period assists in the therapy or even protection against strokes, heart stroke, liver disease and leukemia, amid all kinds of other critical diseases. 

Spotting the position of recent medical, this Department of Surroundings and also Natural Means (DENR) organised this special event with the “7th National Biotechnology Week” from November. 21 years old for you to Twenty six. This occasion coincided together with the Food items and also Substance Administration-led “National Consciousness Week Against Phony Medicines” using the assistance on the pharmaceutic market, along with medical in addition to para-medical specialized businesses.

This week-long celebration seemed to be supported by some other government departments involved in biotechnology study. Some other collaborating gov departments were this sections regarding Science and Technology, Health, and also Agriculture.

Source:
http://www.biotechblog.org/rss.xml

Manila: This Philippine federal government is definitely depending on biotechnology-based options throughout handling critical environmental and meals basic safety difficulties struggling with america.

Environment Admin Ramon Paje, during a the latest event with suv Quezon City paying attention to the 7th Nationwide Biotechnology 7 days, said medical is key in order to approaching crucial the environmental problems facing this Philippines, for example connection between climatic change including droughts, food safety and mitigation of effects via rental destruction.

Biotechnology is generally defined as the field of biology that utilizes residing creatures in addition to bioprocesses within engineering, drugs and other applications.

Paje stated that given the difficulties challenged simply by places such as Australia which can be as a result of climatic change and man-made maladies such as contamination, there is an enormous likely regarding biotechnology throughout protecting as well as enhancing the company’s environment.

The utilization of biotechnology, specifically in food items creation as well as remedies, is debatable trouble in the Australia as well as in different establishing in addition to civilized world.

Paje known that while the advantages of the actual safe utilization of medical throughout other sectors, specifically in agriculture as well as drugs, are actually increasingly recognized by the us government, vehicles identified the various troubles experiencing biotechnology, specially the alleged affect of genetically-modified microorganisms or even GMOs on the some people’s health, pets as well as the atmosphere.

Source:
http://www.biotechblog.org/rss.xml

Bio-Technology can be a study driven scientific disciplines, a mixture of The field of biology along with Technologies. That covers numerous subject matter such as Genetics, bio chemistry , Microbiology, Immunology, Virology, Biochemistry and also Architectural and it is concerned with a great many other themes such as Health and Medication, agriculture and Dog Husbandry, Farming system and Plants Operations, Ecology, mobile or portable medical Soil technology as well as Soil Efficiency, Bio-statistics, Seed Composition, Seeds Technologies etc. Bio-Technology may be the using life, especially cellular material and bacterias in business process.

You will find there’s wonderful setting in this area as the need for biotechnologist are usually increasing within Of india as well as overseas. Medical is most lightly looked as the ability of making use of dwelling bacteria along with their products for the production of foods, drink, treatments or some other good things about mankind, and other canine types.

Regarding two decades back, medical started to be much more of a research (instead of an art form). Aspects of Genetic make-up (called genes) put together in order to contain data that could bring about activity associated with certain proteins (which can be strings of proteins). These meats have their own individual identification along with purpose; many catalyze (help) compound responses, yet others tend to be structural aspects of organizations throughout cellular material. If one now’s able to express an all-natural gene within easy bacterias including Escherichia coli (E. coli), any bacterium moving into digestive tract that has become the actual product living thing for most of medical, it’s possible to possess this particular germs make a great deal of the particular necessary protein numbered pertaining to by the gene, irrespective their source.

Source:
http://www.biotechblog.org/rss.xml

2002 Lecture by Dr Patrick Dixon, ranked as one of the 20 most influential business thinkers alive today (Thinkers 50 2005). Health care trends, future of pharmaceutical industry, biotechnology, stem cells, human cloning, organ regeneration, longevity, ageing, negligible senescence. Life expectancy, genetic modification, pharmacogenomics, medicare and health care budgets.

Originally posted here:
Future of Health Care - medical, health and hospital trends - Biotechnology company keynote 2002 by - Video

It's a controversial treatment, but US approval of stem cell therapies could make this Edinburgh-based biotech firm an Angel of the north for investors.

Read more:

Angel Biotechnology (ABH) - Video